Ligands of Immunopharmacology

IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4) , with an IC 50 of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and

IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4) , with an IC 50 of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and

IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC 50 values of 5 and 56 nM for IRAK4 and TAK1 , respectively. IRAK4-IN-21 effectively inhibits IL-23 production ( IC 50 =0.17 µM) and can be used in studies of

IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC 50 values of 5 and 56 nM for IRAK4 and TAK1 , respectively. IRAK4-IN-21 effectively inhibits IL-23 production ( IC 50 =0.17 µM) and can be used in studies of

IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC 50 values of 3 and 17 nM for IRAK4 and TAK1 , respectively. IRAK4-IN-21 effectively inhibits IL-23 production ( IC 50 =0.10 µM) and can be used in studies of

IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC 50 values of 3 and 17 nM for IRAK4 and TAK1 , respectively. IRAK4-IN-21 effectively inhibits IL-23 production ( IC 50 =0.10 µM) and can be used in studies of

IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC 50 values of 3 and 17 nM for IRAK4 and TAK1 , respectively. IRAK4-IN-21 effectively inhibits IL-23 production ( IC 50 =0.10 µM) and can be used in studies of

IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC 50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphomaForm:PowderIC50&amp Target:IC50: 4 nM (IRAK4)

IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC 50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphomaForm:PowderIC50&amp Target:IC50: 4 nM (IRAK4)

IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC 50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphomaForm:PowderIC50&amp Target:IC50: 4 nM (IRAK4)

IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC 50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphomaForm:PowderIC50&amp Target:IC50: 4 nM (IRAK4)

IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC 50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphomaForm:PowderIC50&amp Target:IC50: 4 nM (IRAK4)